Applications

1439 – Intravesical instillation of sodium hyaluronate (1.6%) & sodium chondroitin sulphate (2.0%) for Painful Bladder Syndrome / Interstitial Cystitis, Recurrent Urinary Tract Infection and Radiation Induced Cystitis

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

iAluRil is instilled into the bladder and held for as long as possible (30 + mins).

Type: Therapeutic

Medical condition this application addresses

iAluRil therapy is indicated to re-establish the glycosaminoglycan layers (GAGs) of the urothelial vesical tissue in cases in which their loss can cause frequent and recurring problems such as Painful Bladder Syndrome (PBS), interstitial cystitis (IC), treatment and prevention of recurrent urinary tract infection, cystitis as a result of Bacillus Calmette ± Guerin therapy, or chemical and radiation therapy.

iAluRil therapy is also indicated in the cases where the loss of the glycosaminoglycan layers (GAGs) is associated with forms of chronic inflammation, in which their composition and integrity appears compromised in different ways.

Application documents

PICO confirmation

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: 11 - 12 August 2016
  • ESC meeting: 8 June 2017
  • MSAC meeting: 27 July 2017